-
Hansoh Pharmaceutical Regains Rights to Ameile After EQRx Partnership Cancellation
•
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced the cancellation of its partnership and licensing agreement with US-based EQRx Inc. (NASDAQ: EQRX) concerning the epidermal growth factor receptor (EGFR) inhibitor Ameile (almonertinib). As a result, the Chinese company will regain research and development (R&D), manufacturing, and commercialization rights to…
-
EQRx Inc. to be Acquired by Revolution Medicines in All-Stock Transaction
•
US-based EQRx Inc. (NASDAQ: EQRX) has revealed that a definitive agreement has been signed for the company to be fully acquired by US-based Revolution Medicines (NASDAQ: RVMD). The transaction will be executed as an all-stock deal, with Revolution issuing shares to EQRx shareholders, anticipating the acquisition of over USD 1…
